Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308670 | 0.85 | BACE1 (0.57) | BACE1CTSD | |
| SCHEMBL4410170 | 0.83 | BACE1 (0.43) | BACE1CTSD | |
| SCHEMBL3224076 | 0.83 | BACE1 (0.43) | BACE1CTSD | |
| SCHEMBL309085 | 0.81 | CTSD (0.58) | BACE1CTSD | |
| SCHEMBL309571 | 0.81 | CTSD (0.48) | BACE1CTSD | |
| SCHEMBL2906866 | 0.81 | BACE1 (0.38) | BACE1CTSD | |
| SCHEMBL4256055 | 0.80 | CTSD (0.59) | BACE1CTSD | |
| SCHEMBL3224796 | 0.80 | BACE1 (0.47) | BACE1CTSD | |
| SCHEMBL4260201 | 0.79 | CTSD (0.61) | BACE1CTSD | |
| SCHEMBL4255806 | 0.79 | CTSD (0.49) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989194-B1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | RUEEGER HEINRICH | 2009-04-16 | — | — | US | disclosed |
| EP-1989194-A1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007093621-A1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | BACE1, BACE2, APP | BACE1 1/4885CTSD 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.